The Global Market for Regenerative Medicine is Projected to Reach US$14.4 Billion by 2022

Need for Effective Therapies that Enhance the Chance of Successful Recovery Drives Demand for Regenerative Medicine in Bone and Joint Applications, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size, and demand forecasts on the global Regenerative Medicine market. The global market for Regenerative Medicine is projected to reach US$14.4 billion by 2022, driven by the growing value of regenerative medicine and its promised benefits in the field of orthopedic surgery.

Regenerative medicine is an offshoot of tissue engineering that deals with stimulation of body’s repair mechanism to heal or replace damaged organs and tissues. Considered as the medicine of the 21^st century, regenerative medicine is a disease-modifying approach that leverages the body’s own healing power and mechanism unlike conventional medicine’s symptomatic therapy approach. The ability to etiologically treat diseases, not possible with any of the conventional treatment methods including surgery, translates into tremendous opportunity for regenerative medicine. Regenerative medicine employs engineered cells, biomaterials, tissues, growth factors or scaffolds, either alone or in combination to facilitate human body augment, replace, repair, or regenerate damaged tissues and organs in the body. While regenerative medicine is still in embryonic stages and faces several hurdles that prevent it from fully delivering its promises, the science as such is generating considerable interest among the scientific community driven in large part due to significant unmet medical needs.

Wound healing and bone & joints are the two major areas where regenerative medicine has and still continues to make significant commercial progress supported by developments in stem cells, tissue engineering, bioengineering and nanotechnology. Opportunities in space will be bolstered by the rapidly aging population and the ensuing rise in diseases and disorders of the bone and joints. Bone grafting is the most preferred treatment for various bone ailments, where autografts are deemed the gold standard. Allogenic bone, demineralized bone matrices and various synthetic biomaterials represent the other common therapies in bone grafting. Owing to certain limitations with autografts, the market is moving towards allografts and other products and techniques such as bone morphogenetic proteins (BMP), synthetic bone grafts, bone cement fillers, osteogenesis, and graft composites. The search for alternatives to autograft and allografts, due to inherent difficulties in sourcing and others, is leading to the development and acceptance of synthetic bone grafts. Engineered bone tissue or bone tissue engineering (BTE) are also witnessing growing interest as a potential alternative to current clinical interventions for bone regeneration or substitution, owing to their unlimited supply. Orthobiologics, a branch of medical science that utilizes biomaterials and other biological products with regenerative capabilities to fuse, join, and stimulate bone growth, is increasingly gaining foothold in the bone graft market.

As stated by the new market research report on Regenerative Medicine, the United States represents the largest market worldwide, supported by high level of awareness, availability of novel therapies, societal aging and a parallel increase in burden of various bone and joint diseases; supportive political policies, government funding and corporate investments; superior clinical outcomes; and increased endorsement from doctors. Asia-Pacific ranks as the fastest growing market worldwide with a CAGR of 18.8% through the analysis period, led by factors such as growing population and healthcare burden; rising incomes and per capita spending on healthcare services; developing healthcare infrastructure; policy led investment commitments in cutting edge medical research; and rise of low cost Asian countries as destinations for affordable orthopedic care.  

Major players covered in the report include AlloSource, Anika Therapeutics, Inc., Bioventus LLC, DePuy Synthes Spine, Inc., Exactech, Inc., Integra LifeSciences Holdings Corp., LifeNet Health, Inc., Medtronic, plc, NovaBone Products LLC, NuVasive, Inc., Orthofix International N.V., Osiris Therapeutics, Inc., Smith & Nephew plc, Stryker Corporation, Wright Medical Technology, Inc. and Zimmer Biomet Holdings, Inc. among others.

The research report titled “Regenerative Medicine: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Regenerative Medicine in value terms for all major geographic markets such as United States, Japan, Europe, Asia-Pacific and Rest of World. Global market for Regenerative Medicine is further analyzed by the following applications- Bone Replacements, Bone Simulators and Tissue Replacements.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.